Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biomatrix Alpha
- Development stage
- Unknown
- Lead developer
- Biosensors International
- Modality
- Small Molecules
- Administration
- Intra-arterial
01
Overview
Biomatrix Alpha (BioMatrix Alpha) is a drug-eluting coronary stent (DES) developed by Biosensors International Group. It features a thin-strut (83-micrometer) cobalt-chromium stent platform with a hybrid design that combines S-shaped connectors for flexibility and straight connectors for longitudinal strength. The device utilizes an abluminal biodegradable polymer coating that elutes umirolimus (also known as biolimus A9 or BA9), a highly lipophilic semi-synthetic analogue of sirolimus. The polymer is fully absorbed within 6 to 9 months, leaving behind a bare-metal stent surface to potentially reduce the risk of late stent thrombosis. Biomatrix Alpha is used in percutaneous coronary intervention (PCI) to treat coronary artery disease, including complex lesions and bifurcations. It has received CE Mark approval but is not available for sale in the United States.
- Brand names
- BioMatrix Alpha
02
Targets
Mechanistic target of rapamycin complex 1FKBP1A
Beyond the preview
Go deeper on Biomatrix Alpha.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biomatrix Alpha.